Follistatin 344 FAQ for Laboratory Researchers
Follistatin 344 (FST-344) is a recombinant or synthetic peptide cassette derived from human follistatin gene transcription, widely utilized in preclinical research to study autocrine and paracrine tissue regulation. This Follistatin 344 FAQ serves as an analytical guide for laboratory investigators, outlining molecular characteristics, reconstituted stability, myostatin-binding mechanisms, and stringent quality control protocols required for valid in vitro and animal model assays.
Quick answer
Follistatin 344 (FST-344) is a recombinant or synthetic peptide cassette derived from human follistatin gene transcription, widely utilized in preclinical research to study autocrine and paracrine tissue regulation. This Follistatin 344 FAQ serves as an analytical guide for laboratory investigators, outlining molecular characteristics, reconstituted stability, myostatin-binding mechanisms, and stringent quality control protocols required for valid in vitro and animal model assays.
Key takeaways
- Follistatin is a monomeric cysteine-rich glycoprotein initially identified in porcine follicular fluid as an inhibitor of follicle-stimulating hormone (FSH) secretion.
- The primary biochemical role of follistatin in experimental settings involves high-affinity neutralization of growth differentiation factor 8 (GDF-8, commonly known as myostatin) and Activin A.
- When designing protocols to investigate myostatin pathways, researchers must choose among several targeted inhibitors.
- Reliable scientific outcomes require research compounds manufactured to strict chemical and biological tolerances.
Structure and Isoform Differentiation of Follistatin 344
Follistatin is a monomeric cysteine-rich glycoprotein initially identified in porcine follicular fluid as an inhibitor of follicle-stimulating hormone (FSH) secretion. Human follistatin exists in multiple distinct isoforms resulting from alternative splicing and post-translational processing. The precursor mRNA generates two primary translation products: a 344-amino acid precursor peptide (Follistatin 344) and a 317-amino acid precursor peptide. Following C-terminal processing, Follistatin 344 yields the mature, circulating 315-amino acid protein (FST-315), whereas the shorter transcript yields FST-288.
In experimental biology, follistatin 344 is frequently investigated due to its extended cassette structure and core functional domains. The protein sequence contains an N-terminal domain followed by three conserved follistatin domains (FS1, FS2, and FS3). Each FS domain features specific disulfide-bonded motifs essential for high-affinity binding to members of the transforming growth factor-beta (TGF-β) superfamily. Researchers often prefer FST-344 variants in recombinant system studies to evaluate precursor sequence cleavage, tissue retention characteristics, and heparin-binding dynamics.
Preclinical Mechanisms: Myostatin and Activin A Neutralization
The primary biochemical role of follistatin in experimental settings involves high-affinity neutralization of growth differentiation factor 8 (GDF-8, commonly known as myostatin) and Activin A. Preclinical studies suggest that follistatin functions as a biological antagonist by sequestering these ligands in the extracellular space, thereby preventing their interaction with Activin type II receptors (ActRIIB) on target cell membranes.
When myostatin or Activin A binds to ActRIIB, it recruits and phosphorylates Activin type I receptors (ALK4 or ALK5), triggering the intracellular phosphorylation of Smad2 and Smad3 transcription factors. Activated Smad complexes translocate to the nucleus to upregulate gene networks that suppress muscle protein synthesis and promote proteolysis. In vitro assays demonstrate that co-incubation with myostatin inhibitors like Follistatin 344 blocks receptor phosphorylation cascades, shifting cellular homeostasis toward anabolic gene expression and satellite cell activation in murine skeletal muscle culture models.
Comparative Analysis: Follistatin 344 vs. Follistatin 315 vs. Ace-031
When designing protocols to investigate myostatin pathways, researchers must choose among several targeted inhibitors. Follistatin 344 represents the full-length precursor construct, which exhibits local tissue-binding propensity due to its basic residues. In contrast, Follistatin 315 is the carboxyl-truncated circulating isoform that exhibits lower affinity for cell-surface heparin sulfates, resulting in greater systemic distribution in rodent models. Another major research tool in this category is Ace-031, a soluble fusion protein consisting of the extracellular domain of ActRIIB linked to the Fc portion of human IgG1. While Follistatin isoforms bind both myostatin and Activins with varying tissue persistence, Ace-031 acts as a circulating decoy receptor that broadly sequesters ActRIIB ligands.
Choosing between these experimental tools depends on the target tissue and research objective. Studies focusing on localized intramuscular gene delivery or autocrine signaling pathways typically utilize follistatin 344 cassette constructs, while investigations into systemic ligand clearance often incorporate soluble decoy receptors or circulating isoforms. For broader context on signal transduction research, consult the PX1 research library.
Analytical Purity Verification and Endotoxin Control
Reliable scientific outcomes require research compounds manufactured to strict chemical and biological tolerances. At PX1 Research, every batch of Follistatin 344 undergoes rigorous analytical testing at an independent, accredited ISO 17025 laboratory. High-Performance Liquid Chromatography (HPLC) is employed to assess chemical purity, ensuring that the target peptide content exceeds 98% relative peak area.
To confirm exact molecular mass and primary structure integrity, Mass Spectrometry (MS)—such as Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF) or Electrospray Ionization (ESI-MS)—is conducted on each lot. Furthermore, because recombinant proteins produced in bacterial or eukaryotic expression systems can retain residual lipopolysaccharides, mandatory chromogenic Limulus Amebocyte Lysate (LAL) testing is performed. PX1 Research guarantees that endotoxin levels remain below 0.1 EU/µg, minimizing unwanted baseline inflammatory signals in primary cell cultures and animal models.
Solubilization and Reconstitution Protocols for Laboratory Use
Lyophilized Follistatin 344 powder must be carefully reconstituted to prevent mechanical denaturation or aggregate formation. The lyophilized cake should be brought to room temperature prior to opening the vial to prevent condensation. Reconstitution should be performed using sterile, endotoxin-free Bacteriostatic Water or Sterile Water for Injection, depending on the intended timeframe of the assay.
Researchers should gently inject the diluent along the inner glass wall of the vial, allowing the solvent to submerge the lyophilized cake. Gentle swirl mixing is recommended; aggressive shaking or vortexing should be strictly avoided, as shear forces can disrupt the tertiary structure and disulfide bonds critical for target receptor binding. For long-term aliquot storage or low-concentration working solutions, adding a carrier protein such as 0.1% Bovine Serum Albumin (BSA) or Human Serum Albumin (HSA) prevents non-specific adsorption to plastic container surfaces.
Storage Parameters and Degradation Dynamics
Lyophilized peptides are susceptible to chemical degradation, including deamidation, oxidation, and peptide bond hydrolysis, if stored improperly. In its un-reconstituted state, dry Follistatin 344 powder remains stable at -20°C for up to 24 months, or at -80°C for extended archival preservation. Desiccant packets should be maintained within secondary packaging to shield the sample from ambient humidity.
Once reconstituted in liquid solution, peptide stability decreases significantly. Reconstituted stock solutions stored at 2°C to 8°C should be utilized within 7 to 14 days. If experimental workflows require longer operational windows, the reconstituted solution must be divided into single-use working aliquots and frozen immediately at -80°C. Repeated freeze-thaw cycles cause cryo-concentration and mechanical shear, leading to irreversible aggregation and Loss of Bioactivity.
In Vitro and Animal Model Research Protocols
In vitro models routinely utilize Follistatin 344 to examine C2C12 myoblast differentiation, protein synthesis kinetics, and gene expression downstream of the Smad2/3 path. Laboratory investigators add reconstituted Follistatin 344 to serum-starved culture media alongside exogenous myostatin or Activin A to generate dose-response inhibition curves via Western blot analysis of phosphorylated Smad proteins.
In vivo preclinical rodent models involve targeted delivery techniques to evaluate local versus systemic tissue adaptation. Research protocols frequently incorporate Western blotting, RT-qPCR, and immunohistochemical staining to measure markers of hypertrophy, such as myonuclear domain density, cross-sectional muscle fiber area, and muscle-specific E3 ubiquitin ligase activity (MuRF-1 and MAFbx). When comparing structural proteins across different pathway models, investigators may also evaluate adjacent tissue remodeling compounds like BPC-157 or anabolic signaling mediators such as IGF-1 LR3.
Sourcing and Chain-of-Custody Standards at PX1 Research
Reproducibility in scientific research depends fundamentally on source reliability. PX1 Research synthesizes and processes research compounds exclusively within state-of-the-art, GMP-compliant facilities located in the United States. Every lot is paired with a transparent, lot-specific Certificate of Analysis (COA) detailing HPLC chromatograms, MS spectra, and quantitative endotoxin levels.
To protect compound integrity during transit, orders are dispatched directly from centralized fulfillment hubs in California and Arizona. PX1 Research provides same-day shipping for orders placed Monday through Friday before cut-off times, ensuring that temperature-sensitive research materials arrive efficiently at university, institutional, and private laboratory facilities. Bulk requirements for high-throughput screening or multi-phase animal studies can be managed directly via our wholesale lab account portal.
Frequently Asked Questions
What is the official research classification of Follistatin 344?
Follistatin 344 is a recombinant research peptide cassette supplied exclusively for in vitro and laboratory experimental investigation. It is not approved for human consumption, therapeutic use, or veterinary administration.
Where is PX1 Research Follistatin 344 synthesized and tested?
All Follistatin 344 distributed by PX1 Research is synthesized in USA-based, GMP-compliant manufacturing facilities and independently batch-tested at an ISO 17025 accredited laboratory.
How is the purity of Follistatin 344 verified?
Purity is verified via High-Performance Liquid Chromatography (HPLC) to confirm peptide content exceeds 98% purity, alongside Mass Spectrometry (MS) to verify exact molecular weight and sequence identity. Every lot includes a downloadable Certificate of Analysis (COA).
What are the acceptable endotoxin limits for PX1 Follistatin 344?
PX1 Research enforces strict endotoxin controls, verifying through chromogenic LAL testing that endotoxin levels are maintained below 0.1 EU/µg to prevent baseline inflammatory interference in cell assays.
How should lyophilized Follistatin 344 be stored upon arrival?
Lyophilized powder should be stored in a dry environment with desiccant at -20°C for routine short/medium-term storage, or at -80°C for long-term archival preservation to prevent hydrolytic degradation.
What solvent is recommended for reconstituting Follistatin 344 in laboratory experiments?
Reconstitution is typically performed using sterile, endotoxin-free Bacteriostatic Water or Sterile Water for Injection. For long-term liquid stability or low-concentration working assays, buffer containing 0.1% carrier protein (such as BSA) is recommended to avoid surface adsorption.
How long is reconstituted Follistatin 344 stable in liquid form?
Reconstituted liquid solutions remain stable for up to 7–14 days when kept refrigerated at 2°C to 8°C. For longer storage, solutions must be divided into single-use aliquots and kept at -80°C, avoiding repeated freeze-thaw cycles.
What are the primary molecular targets of Follistatin 344 in preclinical models?
In vitro and animal models show that Follistatin 344 primarily targets and neutralizes myostatin (GDF-8) and Activin A, preventing their binding to the ActRIIB receptor complex and downregulating Smad2/3 signaling.
How does Follistatin 344 differ structurally from Follistatin 315?
Follistatin 344 is the full-length precursor transcript containing an additional C-terminal domain that undergoes cleavage to form Follistatin 315. In experimental settings, FST-344 variants exhibit different heparin-binding characteristics and tissue retention profiles compared to circulating FST-315.
How does Follistatin 344 compare to Ace-031 in myostatin research?
Follistatin 344 is an endogenous ligand antagonist that binds myostatin and Activin A directly in extracellular space, whereas Ace-031 is an engineered soluble ActRIIB-Fc fusion protein that acts as a decoy receptor binding multiple ActRIIB ligands.
What shipping options and fulfillment locations are used for research orders?
Orders ship directly from PX1 Research facilities in California and Arizona. Standard laboratory orders placed Monday through Friday before cut-off ship same-day to ensure minimal transit time.
Can research institutions establish wholesale or bulk supply accounts for Follistatin 344?
Yes, accredited academic institutions, biotech firms, and contract research organizations (CROs) can apply for dedicated institutional pricing and bulk lot reservation through the PX1 Research wholesale portal.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.